Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A phase III trial in patients with metastatic nonsmall cell lung carcinoma

Cancer

Volumn 92, Issue 10, 2001, Pages 2639-2647

  Sweeney, Christopher J ^a,b   Zhu, Junming ^a,b,c,e   Sandler, Alan B ^d   Schiller, Joan ^e,f   Belani, Chandra P ^a   Langer, Corey ^a   Krook, James ^b   Harrington, David ^c   Johnson, David H ^c,d,g  

^a Division of Hematology and Oncology   (United States)

^b FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g Duluth Clinic   (United States)

Author keywords

Chemotherapy; Eastern Cooperative Oncology Group; Nonsmall cell lung carcinoma; Performance status 2

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PATIENT SELECTION; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TAXOIDS;

EID: 0035889915     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8     Document Type: Article

References (32)

1. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature
2. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer
3. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - Report of a Canadian multicenter randomized trial
4. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
5. Randomized trial comparing cisplatin with cisplatin plus navelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group study
6. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
7. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
8. Prognostic factors in advanced nonsmall cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group trials from 1981-1992
9. Prognostic factors for survival in advanced non-small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients
10. Chemotherapy for advanced non-small cell lung cancer: Past present and future
11. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy
12. A randomized Phase III trial of four chemotherapy regimens in advanced non-small lung cancer (NSCLC)
13. Chemotherapy in non-small cell lung cancer. Meta-analysis using updated data on individual patients from 52 randomized clinical trials
14. Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised Phase II study in locally advanced or metastatic non-small cell lung cancer
15. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
16. Randomized Phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer
17. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter Phase III trial
18. Randomized Phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer
19. Gemcitabine plus best supportive care (BSC) vs BSC inoperable non-small cell lung cancer - A randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small cell lung cancer
20. Gemcitabine plus vinorelbine in non-small cell lung carcinoma patients age 70 years or older or patients who can not receive cisplatin
21. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer
22. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer
23. Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: A Phase II study
24. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer
25. The MILES (Multicenter Italian Lung Cancer Study in the Elderly Study) Phase 3 trial: Gemcitabine + vinorelbine versus vinorelbine versus gemcitabine in elderly advanced NSCLC patients
26. 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial
27. A Phase I study of carboplatin and paclitaxel in non-small cell lung cancer: A University of Colorado Cancer Center study
28. Paclitaxel 3-hour infusion given alone and combined with carboplatin: Preliminary results of dose escalation trials
29. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer
30. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer
31. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer
32. A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: A Phase II randomized trial